Events and Networking

Expand Your Network at One of Biocom’s 150+ Annual Events

Big Data Executive Summit: All About Us: Getting Personal with Precision Medicine & Oncology

When:

Wed Nov 29 15:00:00 GMT 2017 - Thu Nov 30 00:30:00 GMT 2017

Where:

The Alexandria
10996 Torreyana Road
San Diego, CA 92121

Register

Big Data Executive Summit: All About Us: Getting Personal with Precision Medicine & Oncology
This one-day event will feature illuminating discussions focused specifically on the intersection of big data, precision medicine and oncology. The program will include dynamic keynote presentations, panel discussions, and interactive use-case sessions with local industry leaders offering practical ways to make the strategic and technological decisions critical to Big Data success. Best-in-class technology partners will also be on hand to demo technology and services. This event is a great opportunity for company executives and senior management involved in both the strategy, application and technological decision making affecting Big Data programs. 

*Interested in a half-day rate? Contact Ashleigh Farver for details and admission fees. 

Agenda-At-A-Glance
7:00am to 8:00am | Networking Breakfast & Registration

8:00am to 8:15am | Welcome Remarks 

8:15am to 9:00am | Opening Keynote | Where is Precision Medicine Headed
Stephanie Devaney, Deputy Director, All of Us Research Program, National Institutes of Health

9:15am to 10:15am | Local Perspective on Precision Medicine
Moderator:
Beth Anne Baber, PhD MBA, Founder, CEO, CSO, STORM Real World Health, Inc. 

Panelists: 
Dawn Barry, Vice President, Applied Genomics, Illumina
Camille Nebeker, Ed.D., M.S.,
 Research Ethics Consultant, All of Us Research Program, Assistant Professor, ​Family Medicine and Public Health, School of Medicine, UC San Diego
David Wellis, CEO, San Diego Blood Bank

10:30am to 11:30am | Current State of Cancer Treatment Today
Moderator:
David Nelson,
CEO, Splash Pharmaceuticals, Inc. 
Panelists:
 
Stephane Richard, President & COO, CureMatch
Ingo Chakravarty, CEO, Navican
Jeremy Pine, Information Technology Section Chief, California Cancer Registry
Razelle Kurzrock, MD, Chief Medical Advisor & Co-Founder, CureMatch, Inc., Chief, Division of Hematology and Oncology, UCSD School of Medicine, Senior Deputy Director, Director, Center for Personalized Cancer Therapy, Director, Clinical Trials Office, UCSD Moores Cancer Center

11:30am to 12:15pm | Networking Lunch

12:15pm to 1:00pm |
 Lunch Keynote
Reny Aniline, Solutions Executive, IBM Watson for Genomics

1:00pm to 1:30pm | Data Integration and Utility for Precision Medicine​
Corina Shtir, Head of Precision Medicine, Thermo Fisher Scientific 

1:45pm to 2:30pm | How do you use Big Data to Drive Reimbursement?
Moderator:
David Wetherelt,
Business Development, 3M Health Information Systems
Panelists:
Benjamin Yu,
 M.D., Ph.D., Vice President, Medical Informatics and Genomics, Interpreta
Julie Rogers, Senior Solution Architect, 3M Information Systems

2:30pm to 3:00pm | What do you do with the Data: Connecting the Dots
Moderator:
Nardo Manaloto,
CEO, Catalaize
Panelists:
Wen Dombrowski,
MD, MBA, Chief Convergence Officer, Catalaize

Jason Crites, Healthcare Life Sciences Solutions Leader, Storage and HPC, IBM
Mike Norman, Director, San Diego Supercomputer Center

3:00pm to 3:30pm | Analytics Capabilities and Solutions for Medical Image Analysis at the Cloud Level and the Edge
Introduction:
Chris Orlando,
Co-Founder, ScaleMatrix
Presenter:
Jackson He,
Senior Director of Strategic Planning, Intel Artificial Intelligence Product Group (AIPG), Intel Corporation 

3:45pm to 4:30pm | Closing Keynote | Economics of Precision Medicine
John Mattison, Asst. Med. Director, Chief Health Information Officer, Kaiser Permanente 



Sponsors: 

User-added image


User-added image


User-added image

User-added image
User-added image

Price of Admission

Biocom Member

Today's Price: 180.0

Important Dates

Amount

Registration Before

Registration Before

Registration Before

Refund after Mon Nov 27 00:00:00 GMT 2017

180.0

Refund after

Refund after

Biocom Non-member

Today's Price: 300.0

Important Dates

Amount

Registration Before

Registration Before

Registration Before

Refund after Mon Nov 27 00:00:00 GMT 2017

300.0

Refund after

Refund after

  • Meet Our Speakers

    Reny Aniline, Solutions Executive, IBM Watson for Genomics
    Reny Aniline has more than 15 years of experience in the diagnostics and life sciences industries.  For the past 10 years, he has focused on DNA Sequencing and Genomics applications in both clinical and research markets.  Reny is currently working with IBM Watson technology to help transform cancer care with cognitive computing.  He received his BS in Biological Sciences from UC Irvine and MBA from Anderson University.

    Beth Anne Baber, PhD MBA, Founder, CEO, CSO, STORM Real World Health, Inc.
    Beth Anne ​is founder and CEO of STORM Real World Health, an early-stage software start-up aiming to create profound and lasting positive changes in healthcare.  These changes will empower patients, caregivers, physicians, and the medical research community by facilitating access to meaningful health information through analytics.  Following her son’s cancer diagnosis, Beth Anne became a patient advocate working closely with Congress on personalized medicine and pediatric medical research initiatives.  In addition to generating funding for cancers of children, adolescents and young adults in the Department of Defense, Beth Anne was instrumental in establishing a $126M NIH genomics initiative to understand the link between childhood cancers and structural birth defects. She’s a member of several advisory boards, including Global Genes and the Stand-Up to Cancer Pediatric Cancers Dream Team. Prior to STORM, Beth Anne was CEO of a nonprofit focused on supporting promising discoveries through the development pipeline and a cancer geneticist at the Salk Institute. Beth Anne received her MBA from UCSD Rady School of Management and her PhD from The Scripps Research Institute.
     
    Dawn Barry, Vice President, Applied Genomics, Illumina
    Dawn Barry is the Vice President of Applied Genomics at Illumina where she has spent the last 12 years developing markets and products to unlock the power of the genome to improve human health and well-being.  In her current role, Dawn integrates market development strategies with product and business model innovation to accelerate genomics in medicine and personal healthcare.  At the heart of her motivation, Dawn believes that genomics holds the promise to address the biggest challenges of the 21st century including unlimited demand for healthcare, nutritious and plentiful food distribution, and threats from infectious agents.  She advocates passionately for the promise that genomics holds to impact every person on the planet, whether it’s through our healthcare, in our homes, or in the environment we all live in.  Dawn joined Illumina in 2005 as their first market development specialist and has since held leadership roles in a number business units, sales, marketing, and market development for the Company.  

    Ingo Chakravarky, CEO, Navican
    Ingo Chakravarty is the President & CEO of NAVICAN. He joined Intermountain Healthcare in June 2016, spinning off NAVICAN in October 2016. He previously served in senior roles at Genmark Diagnostics, Gen-Probe, Roche Diagnostics, and Ventana Medical Systems here in the United States and in Europe. Ingo graduated from Friedrich Haecker School in Germany with a degree in electrical engineering. His leadership philosophy is grounded in collective intelligence, goal orientation and personal accountability as well as in fairness and tolerance. Ingo thrives in environments that are energetic, ambitious and challenging while providing room for innovation and creativity.
     
    Jason Crites, Healthcare Life Sciences Solutions Leader, Storage and HPC, IBM
    Jason Crites, an industry solutions executive at IBM, is responsible for creating and driving storage & big data solutions for healthcare and life science organizations. His primary focus is helping healthcare organizations improve care and lower costs by utilizing new infrastructure technologies for precision medicine and oncology.
     
    Stephanie Devaney, Deputy Director, All of Us Research Program, National Institutes of Health
    Stephanie Devaney is the Deputy Director of the All of Us Research Program at the National Institutes of Health. Prior to this she led the coordination of the Precision Medicine Initiative from the Office of the Chief of Staff at the White House. In this role she coordinated the many components of the Initiative and guided the vision of the overall effort, along with the many federal partners. Before joining the White House, Stephane worked in the Office of the Director at the National Institutes of Health. There she helped advance policies critical to biomedical research and the NIH mission and assisted in the development of programs and research initiatives to advance national scientific priorities, including the Precision Medicine Initiative. Prior to that, Stephanie was a researcher at the Genetics and Public Policy Center at Johns Hopkins University. There she conducted research on pharmacogenetics and drug labeling; performed a meta-analysis of non-invasive fetal gender genetic testing; and was involved in public engagement surrounding the many ethical and social issues that are emerging with novel genomic technologies. Stephanie received her Ph.D. in Molecular Genetics from the George Washington University and her B.S. in Biology from The Ohio State University.

    Wen Dombrowski, MD, MBA, Chief Convergence Officer, Catalaize
    Wen Dombrowski, MD, MBA is a geriatrics physician executive with a unique perspective bridging clinical, technical, business, design, ethics and policy expertise. She is passionate about building ecosystems, connecting needs to resources, identifying and addressing root causes of complex systems problems, and impacting culture change. Dr. Dombrowski creates technology-enabled services, business models and care models to improve lives using human-centered design thinking, data analytics, digital communication technologies, and interdisciplinary collaboration. Dr. Dombrowski is the founding principal of CATALAIZE that advises a wide range of healthcare organizations, technology companies, and investors on innovation and emerging technologies. She has also worked in technology startups, managed care, home care, nursing homes, community health centers, hospitals, and other settings along the continuum of care. Dr. Dombrowski was previously Chief Medical Information Officer (CMIO+CIO) for a state-wide homecare provider, the Technology Strategy lead for a large integrated delivery network's Value-Based Care initiatives, Clinical Informatics Director at a multi-specialty network of community clinics, and Medical Director at a managed care plan. 

    Jackson He, Senior Director of Strategic Planning, Intel Artificial Intelligence Product Group (AIPG), Intel Corporation 
    Dr. He is a Senior Director of Intel AI Product Group leading Intel AI business and product strategy development. He also served as General Manager of Intel Asia and Pacific R&D Ltd. and Intel Software and Services Group (SSG) PRC for 6 years, very familiar with Intel business in China. Dr. He joined Intel in 1995, served in various leadership roles within Intel IT and Intel Labs, DCG, and SSG. In recent years, Dr. He focused on enterprise and cloud solution evangelization, a key driver of Intel Cloud Builder Program in China and an Advisor to Open Data Alliance (ODCA).  Dr. He has extensive experience working with enterprise, Telco, and IPDC customers in China. He served as Intel’s representative at several standards groups (OASIS, WS-I, DMTF, etc.). He also deeply involved in healthcare vertical. As the Intel rep, Dr. He led to definition of Reginal Healthcare Information System (RHTS) blueprint in China. He also served on China Senior Care Expert Committee and led explorations on healthcare solutions on IA. Dr. He has been active in open source solutions for cloud and big data. He initiated China Open Source Cloud League (COSCL and led Intel/Cloudera collaboration on big data solutions for customers in China. Dr. He received Ph.D. and MBA from the University of Hawaii.
     
    Razelle Kurzrock, MD, Chief Medical Advisor & Co-Founder, CureMatch, Inc., Chief, Division of Hematology and Oncology, UCSD School of Medicine, Senior Deputy Director, Director, Center for Personalized Cancer Therapy, Director, Clinical Trials Office, UCSD Moores Cancer Center
    Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine.   Dr. Kurzrock received her MD degree from the University of Toronto and has almost 700 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building. Using algorithms developed with UCSD Supercomputer Center colleagues and her own precision medicine experience, Dr. Kurzrock co-founded CureMatch, Inc. 
     
    Nardo Manaloto, CEO, Catalaize
    Nardo Manaloto is a healthcare technology industry veteran with over 25 years of management experience in solving healthcare challenges using innovation, user centered design, enterprise architecture, and new technologies. He is a strategic thought leader in ecosystem development, platform design, solution concepts, systems analysis, product architecture, hybrid value chains, and applied innovations to solve complex problems using current and emerging technologies. Nardo has worked with many healthcare stakeholders including health plans, providers, patients, and community points of view. He previously headed up Kaiser Permanente’s Innovation, Solution Design, and System Transition groups and has applied full innovation life cycle to scale new solutions and sunset legacy systems on an enterprise level. He has also worked with technology startups including roles as Chief Product Officer, Chief Innovation Officer, and Chief Technology Officer with companies that utilize artificial intelligence algorithms and capabilities. Nardo has won several healthcare innovation awards for solutions spanning the areas of artificial intelligence, secure messaging, communication and social collaboration, mobile applications, and virtual care.

    John Mattison, Asst. Med. Director, Chief Health Information Officer, Kaiser Permanente 
    John Mattison, MD practiced clinical medicine in internal medicine, critical care, trauma medicine, hyperbaric medicine, primary care, and preventive medicine, prior to becoming the Chief Health Information Officer and Assistant Medical Director at Kaiser Permanente’s largest region, SCAL.  He led the largest electronic health record initiative in the US, and founded the international XML standard for healthcare interoperability.  He is advisory board member to several global blockchain initiatives and has given numerous keynotes and workshops on various aspects of blockchain, including transparency into the value tradeoffs that underlie specific architectures for distributed ledgers.  He is an active contributor to global research initiatives in genomics and chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), co-leads the national KP virtual care workgroup with oversight of telemedicine, virtual care and remote monitoring, and is a member of the National KP Precision Medicine Advisory Board.  Ten years ago, he built a machine learning team that has achieved powerful results mining text data to improve patient safety, quality outcomes, and operational efficiency across the organization.  He was a founding board member of the Kaiser Permanente Innovation Board.  He is a board member of multiple not-for-profit boards dedicated to improving health, wellness, and resilience of diverse communities, especially for early childhood.  He is passionate about using modern technology to restore ancient wisdom and creating a ‘behavioral symphony for wellness’, and ‘social equity by design’. 

    Camille Nebeker, Ed.D., M.S.Research Ethics Consultant, All of Us Research Program, Assistant Professor, ​Family Medicine and Public Health, School of Medicine, UC San Diego
    Camille Nebeker is on the UCSD School of Medicine faculty affiliated with the Center for Wireless and Population Health Systems located in the Qualcomm Institute. Her expertise is in applied research ethics with a focus on community research capacity building via education and on the ethical dimensions of emerging technologies used in health research (e.g., consent, privacy, data managemetn). She leads the BRIC and CORE initiatives and consults with the NIH-supported Precision Medicine Initiative’s All of Us Research Program.

    David Nelson, CEO, Splash Pharmaceuticals, Inc. 
    Dr. Nelson is the President and CEO of Splash Pharmaceuticals which is currently in a clinical trial with an innovative therapeutic in ovarian cancer.  He has over 30 years of scientific and management experience in the biopharmaceutical and diagnostic industries and is the past Chairman of the Board for the Clearity Foundation.  Dr. Nelson previously served as Chief Strategy Officer of Provista Diagnostics, President and CEO of a proprietary mobile health “mHealth” company which he sold, Founder/President/Director and CEO of Epic Sciences, Vice President of Business Development of Amalyte Pharmaceuticals, and President of the Life Science Group.  Before that, Dr. Nelson worked at Anadys Pharmaceuticals, Aurora Biosciences, the National Human Genome Research Institute at the National Institutes of Health, 3M, and the University of Minnesota.  Dr. Nelson has been the Principal Investigator on numerous Phase I and II SBIR grants, has a number of peer-reviewed publications, book chapters and patent applications and has been an invited speaker at national meetings in business development, investor relations, and science.

    Mike Norman, Director, San Diego Supercomputer Center
    Dr. Michael L. Norman, named SDSC interim director in June 2009 and appointed to the position of director in September 2010, is a distinguished professor of physics at UC San Diego and a globally recognized astrophysicist. Dr. Norman is a pioneer in using advanced computational methods to explore the universe and its beginnings. In this capacity, he has directed the Laboratory for Computational Astrophysics -- a collaborative effort between UC San Diego and SDSC resulting in the Enzo community code for astrophysics and cosmology in use worldwide. Dr. Norman is the author of over 300 research articles in diverse areas of astrophysics, including star and galaxy formation, the evolution of intergalactic medium, as well as numerical methods. Dr. Norman's work has earned him numerous honors, including Germany's prestigious Alexander von Humboldt Research Prize, the IEEE Sidney Fernbach Award, and several HPCC Challenge Awards. He also is a Fellow of the American Academy of Arts and Sciences, and the American Physical Society. He holds an M.S. and Ph.D. in engineering and applied sciences from UC Davis, and in 1984 completed his post-doctoral work at the Max Planck Institute for Astrophysics in Garching, Germany.

    Chris Orlando, Co-Founder, ScaleMatrix
    Chris is the Co-Founder of ScaleMatrix and leads the company's commercial and strategic efforts.   Prior to ScaleMatrix, Chris served as president of the Complex Drive Data Center Group for four years, in addition to developing a number of hosting and colocation brands in the early 2000’s.  Today, Chris is involved in expanding the reach and breadth of the ScaleMatrix brand, which offers clients some of the highest density, and most energy efficient hosting platforms in the world.
     
    Jeremy Pine, Information Technology Section Chief, California Cancer Registry
    Jeremy Pine re-joined the California Cancer Registry in 2014 after having been with the Cancer Registry previously from 2007-2011. He is an experienced leader with business operations roots that has spent the last several years in technology business development and project management, leading teams in defining, designing, and delivering dozens of high impact web product and enterprise web solutions. His goal is to energize teams by establishing a common vision and deliver valuable software. Jeremy currently serves as the Information Technology Section Chief for the California Cancer Registry managing the organizations electronic reporting initiatives.

    Stephane Richard, President & COO, CureMatch
    With over fifteen years of international business development experience, Stephane brings to CureMatch his experience of the biotech industry, strategy, management and an exceptional network of collaborators. Since 2006, Stephane has been the Founder & President of French BioBeach, an organization promoting business between Southern California and European Life science groups. As an author of 17 scientific papers and 6 patents, Stephane received a Ph.D. in biophysics from the University Joseph Fourier in Grenoble, France. He has served as a scientist at Sapphire Energy, the Salk Institute for Biological Studies, and visiting scientist at the Sanford-Burnham Prebys Medical Discovery Institute, before holding managerial positions in biotech. Stephane acted as CEO of CureMatch since its incorporation in October 2015 until November 2016 and is now acting as President & COO.

    Julie Rodgers, Senior Solution Architect, 3M Information Systems
    Julie Rodgers is a senior strategic operations, program manager, and solution architect with over 20 years of experience in complex and large-scale project management and multi-project program leadership roles. Julie has been with 3M HIS for four years, architecting data solutions to drive population health management and payment reform.  Julie has worked in the healthcare industry for over a decade, managing large projects from payment systems to electronic health records. Prior to 3M, Julie worked as a management consultant, utilizing her technical expertise and operational management skills to simplify complex organizational transitions. Julie has extensive consulting experience in Strategic Planning, Change Management, IT solution design, development, implementation, and production support.
     
    Corina Shtir, Head of Precision Medicine, Thermo Fisher Scientific 
    Dr. Corina Shtir is Head of Precision Medicine at Thermo Fisher Scientific. She joined the company in 2013, from the Wellcome Trust Diabetes and Inflammatory Lab in Cambridge, UK. Her expertise spans many areas, including population genetics, biostatistics, statistical genetics, mathematics, epidemiology, all of which enable her to take an integrative approach to driving population-scale programs for both rare and complex disorders.
    In order to bring Precision Medicine initiatives to scale in a cost-efficient and timely manner, we need to understand the full molecular profile of an individual, including genomics, proteomics, metabolomics, immunology, microenvironment, and microbiome, while managing vast amounts of patient data in a secure and collaborative environment. Thermo Fisher Scientific collaborates and enables some of the most ambitious programs worldwide by providing thought leadership and by creating applications that are implemented at large scale within both the research and clinical environments, driving the entire eco-system of health care through groundbreaking and sustainable solutions. We joined the Cancer Moonshot effort for the Blood Profiling Atlas to develop a public database that will make it easier for oncologists to access liquid biopsy information when diagnosing patients, and work to expand into the new proteogenomic era.
     
    David Wellis, CEO, San Diego Blood Bank
    David is a cell biologist with over 25 years’ experience in the life science industry and currently serves as the CEO of the San Diego Blood Bank (SDBB).  SDBB is dedicated to community health by providing a reliable supply of blood to patients in need throughout Southern California. Our vision is to further ensure the health of our community by simultaneously delivering related health and wellness education and services and extending into research.  SDBB is fortunate to be enrolling All of Us Research Program participants through partnerships with the Scripps Translational Science Institute and the California Precision Medicine Consortium. David joined SDBB following his tenure at a variety of companies that develop biologics, and tools for biomedical research, diagnostic and applied markets, including BioAtla, Illumina, GenVault and Axon Instruments.  David received his B.S. from UC Irvine, an M.S. and Ph.D. from Emory University, postdoctoral training at Tufts University and UC Berkeley, and business training at Leavey Business School of Santa Clara University and Haas Business School at UC Berkeley.

    David Wetherelt, Business Development, 3M Health Information Systems
    David Wetherelt, Director, Business Development for 3M Health Information Systems, has been a leader for organizations that were in the forefront of major technology shifts throughout his career. He has worked to create strategic partnerships with technology and service providers worldwide to enable the deployment of new technologies and business strategies. His focus has been on next generation high-speed mobile networks and innovative voice, video and healthcare technologies. Prior to 3M, he co-founded digifitlife, a next generation healthcare applications and services company. Previously, he was also a Senior Manager with Cisco Systems and held strategic roles at Hearme, Stellent, MapInfo and Interleaf. Follow David on Twitter at @davidwetherelt.
     
    Benjamin Yu, M.D., Ph.D., Vice President, Medical Informatics and Genomics, Interpreta
    Dr. Benjamin Yu is the VP of Medical Informatics and Genomics at Interpreta, a San Diego startup recently named 2017 Cool Vendor in Healthcare by Gartner. Prior to Interpreta, Dr. Yu was on faculty at University of California San Diego and Institute for Genomic Medicine. He brings his experience as a scientific leader in human variation and genomics with more than 10 years of research funded by the NIH, California Institute for Regenerative Medicine, and the Bill and Melinda Gates Foundation. Dr. Yu received his M.D., Ph.D. and residency training at Washington University. Dr. Yu is board-certified in dermatology and has been licensed to practice medicine in California since 2002. He continues to participate in training students and residents in dermatology and pharmacogenomics and serves on Biocom's Big Data Committee.
     
     
     

    a0d2A00000EZ8u4QAD

    Go
  • Meet Our Speakers

    Reny Aniline, Solutions Executive, IBM Watson for Genomics
    Reny Aniline has more than 15 years of experience in the diagnostics and life sciences industries.  For the past 10 years, he has focused on DNA Sequencing and Genomics applications in both clinical and research markets.  Reny is currently working with IBM Watson technology to help transform cancer care with cognitive computing.  He received his BS in Biological Sciences from UC Irvine and MBA from Anderson University.

    Beth Anne Baber, PhD MBA, Founder, CEO, CSO, STORM Real World Health, Inc.
    Beth Anne ​is founder and CEO of STORM Real World Health, an early-stage software start-up aiming to create profound and lasting positive changes in healthcare.  These changes will empower patients, caregivers, physicians, and the medical research community by facilitating access to meaningful health information through analytics.  Following her son’s cancer diagnosis, Beth Anne became a patient advocate working closely with Congress on personalized medicine and pediatric medical research initiatives.  In addition to generating funding for cancers of children, adolescents and young adults in the Department of Defense, Beth Anne was instrumental in establishing a $126M NIH genomics initiative to understand the link between childhood cancers and structural birth defects. She’s a member of several advisory boards, including Global Genes and the Stand-Up to Cancer Pediatric Cancers Dream Team. Prior to STORM, Beth Anne was CEO of a nonprofit focused on supporting promising discoveries through the development pipeline and a cancer geneticist at the Salk Institute. Beth Anne received her MBA from UCSD Rady School of Management and her PhD from The Scripps Research Institute.
     
    Dawn Barry, Vice President, Applied Genomics, Illumina
    Dawn Barry is the Vice President of Applied Genomics at Illumina where she has spent the last 12 years developing markets and products to unlock the power of the genome to improve human health and well-being.  In her current role, Dawn integrates market development strategies with product and business model innovation to accelerate genomics in medicine and personal healthcare.  At the heart of her motivation, Dawn believes that genomics holds the promise to address the biggest challenges of the 21st century including unlimited demand for healthcare, nutritious and plentiful food distribution, and threats from infectious agents.  She advocates passionately for the promise that genomics holds to impact every person on the planet, whether it’s through our healthcare, in our homes, or in the environment we all live in.  Dawn joined Illumina in 2005 as their first market development specialist and has since held leadership roles in a number business units, sales, marketing, and market development for the Company.  

    Ingo Chakravarky, CEO, Navican
    Ingo Chakravarty is the President & CEO of NAVICAN. He joined Intermountain Healthcare in June 2016, spinning off NAVICAN in October 2016. He previously served in senior roles at Genmark Diagnostics, Gen-Probe, Roche Diagnostics, and Ventana Medical Systems here in the United States and in Europe. Ingo graduated from Friedrich Haecker School in Germany with a degree in electrical engineering. His leadership philosophy is grounded in collective intelligence, goal orientation and personal accountability as well as in fairness and tolerance. Ingo thrives in environments that are energetic, ambitious and challenging while providing room for innovation and creativity.
     
    Jason Crites, Healthcare Life Sciences Solutions Leader, Storage and HPC, IBM
    Jason Crites, an industry solutions executive at IBM, is responsible for creating and driving storage & big data solutions for healthcare and life science organizations. His primary focus is helping healthcare organizations improve care and lower costs by utilizing new infrastructure technologies for precision medicine and oncology.
     
    Stephanie Devaney, Deputy Director, All of Us Research Program, National Institutes of Health
    Stephanie Devaney is the Deputy Director of the All of Us Research Program at the National Institutes of Health. Prior to this she led the coordination of the Precision Medicine Initiative from the Office of the Chief of Staff at the White House. In this role she coordinated the many components of the Initiative and guided the vision of the overall effort, along with the many federal partners. Before joining the White House, Stephane worked in the Office of the Director at the National Institutes of Health. There she helped advance policies critical to biomedical research and the NIH mission and assisted in the development of programs and research initiatives to advance national scientific priorities, including the Precision Medicine Initiative. Prior to that, Stephanie was a researcher at the Genetics and Public Policy Center at Johns Hopkins University. There she conducted research on pharmacogenetics and drug labeling; performed a meta-analysis of non-invasive fetal gender genetic testing; and was involved in public engagement surrounding the many ethical and social issues that are emerging with novel genomic technologies. Stephanie received her Ph.D. in Molecular Genetics from the George Washington University and her B.S. in Biology from The Ohio State University.

    Wen Dombrowski, MD, MBA, Chief Convergence Officer, Catalaize
    Wen Dombrowski, MD, MBA is a geriatrics physician executive with a unique perspective bridging clinical, technical, business, design, ethics and policy expertise. She is passionate about building ecosystems, connecting needs to resources, identifying and addressing root causes of complex systems problems, and impacting culture change. Dr. Dombrowski creates technology-enabled services, business models and care models to improve lives using human-centered design thinking, data analytics, digital communication technologies, and interdisciplinary collaboration. Dr. Dombrowski is the founding principal of CATALAIZE that advises a wide range of healthcare organizations, technology companies, and investors on innovation and emerging technologies. She has also worked in technology startups, managed care, home care, nursing homes, community health centers, hospitals, and other settings along the continuum of care. Dr. Dombrowski was previously Chief Medical Information Officer (CMIO+CIO) for a state-wide homecare provider, the Technology Strategy lead for a large integrated delivery network's Value-Based Care initiatives, Clinical Informatics Director at a multi-specialty network of community clinics, and Medical Director at a managed care plan. 

    Jackson He, Senior Director of Strategic Planning, Intel Artificial Intelligence Product Group (AIPG), Intel Corporation 
    Dr. He is a Senior Director of Intel AI Product Group leading Intel AI business and product strategy development. He also served as General Manager of Intel Asia and Pacific R&D Ltd. and Intel Software and Services Group (SSG) PRC for 6 years, very familiar with Intel business in China. Dr. He joined Intel in 1995, served in various leadership roles within Intel IT and Intel Labs, DCG, and SSG. In recent years, Dr. He focused on enterprise and cloud solution evangelization, a key driver of Intel Cloud Builder Program in China and an Advisor to Open Data Alliance (ODCA).  Dr. He has extensive experience working with enterprise, Telco, and IPDC customers in China. He served as Intel’s representative at several standards groups (OASIS, WS-I, DMTF, etc.). He also deeply involved in healthcare vertical. As the Intel rep, Dr. He led to definition of Reginal Healthcare Information System (RHTS) blueprint in China. He also served on China Senior Care Expert Committee and led explorations on healthcare solutions on IA. Dr. He has been active in open source solutions for cloud and big data. He initiated China Open Source Cloud League (COSCL and led Intel/Cloudera collaboration on big data solutions for customers in China. Dr. He received Ph.D. and MBA from the University of Hawaii.
     
    Razelle Kurzrock, MD, Chief Medical Advisor & Co-Founder, CureMatch, Inc., Chief, Division of Hematology and Oncology, UCSD School of Medicine, Senior Deputy Director, Director, Center for Personalized Cancer Therapy, Director, Clinical Trials Office, UCSD Moores Cancer Center
    Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine.   Dr. Kurzrock received her MD degree from the University of Toronto and has almost 700 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building. Using algorithms developed with UCSD Supercomputer Center colleagues and her own precision medicine experience, Dr. Kurzrock co-founded CureMatch, Inc. 
     
    Nardo Manaloto, CEO, Catalaize
    Nardo Manaloto is a healthcare technology industry veteran with over 25 years of management experience in solving healthcare challenges using innovation, user centered design, enterprise architecture, and new technologies. He is a strategic thought leader in ecosystem development, platform design, solution concepts, systems analysis, product architecture, hybrid value chains, and applied innovations to solve complex problems using current and emerging technologies. Nardo has worked with many healthcare stakeholders including health plans, providers, patients, and community points of view. He previously headed up Kaiser Permanente’s Innovation, Solution Design, and System Transition groups and has applied full innovation life cycle to scale new solutions and sunset legacy systems on an enterprise level. He has also worked with technology startups including roles as Chief Product Officer, Chief Innovation Officer, and Chief Technology Officer with companies that utilize artificial intelligence algorithms and capabilities. Nardo has won several healthcare innovation awards for solutions spanning the areas of artificial intelligence, secure messaging, communication and social collaboration, mobile applications, and virtual care.

    John Mattison, Asst. Med. Director, Chief Health Information Officer, Kaiser Permanente 
    John Mattison, MD practiced clinical medicine in internal medicine, critical care, trauma medicine, hyperbaric medicine, primary care, and preventive medicine, prior to becoming the Chief Health Information Officer and Assistant Medical Director at Kaiser Permanente’s largest region, SCAL.  He led the largest electronic health record initiative in the US, and founded the international XML standard for healthcare interoperability.  He is advisory board member to several global blockchain initiatives and has given numerous keynotes and workshops on various aspects of blockchain, including transparency into the value tradeoffs that underlie specific architectures for distributed ledgers.  He is an active contributor to global research initiatives in genomics and chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), co-leads the national KP virtual care workgroup with oversight of telemedicine, virtual care and remote monitoring, and is a member of the National KP Precision Medicine Advisory Board.  Ten years ago, he built a machine learning team that has achieved powerful results mining text data to improve patient safety, quality outcomes, and operational efficiency across the organization.  He was a founding board member of the Kaiser Permanente Innovation Board.  He is a board member of multiple not-for-profit boards dedicated to improving health, wellness, and resilience of diverse communities, especially for early childhood.  He is passionate about using modern technology to restore ancient wisdom and creating a ‘behavioral symphony for wellness’, and ‘social equity by design’. 

    Camille Nebeker, Ed.D., M.S.Research Ethics Consultant, All of Us Research Program, Assistant Professor, ​Family Medicine and Public Health, School of Medicine, UC San Diego
    Camille Nebeker is on the UCSD School of Medicine faculty affiliated with the Center for Wireless and Population Health Systems located in the Qualcomm Institute. Her expertise is in applied research ethics with a focus on community research capacity building via education and on the ethical dimensions of emerging technologies used in health research (e.g., consent, privacy, data managemetn). She leads the BRIC and CORE initiatives and consults with the NIH-supported Precision Medicine Initiative’s All of Us Research Program.

    David Nelson, CEO, Splash Pharmaceuticals, Inc. 
    Dr. Nelson is the President and CEO of Splash Pharmaceuticals which is currently in a clinical trial with an innovative therapeutic in ovarian cancer.  He has over 30 years of scientific and management experience in the biopharmaceutical and diagnostic industries and is the past Chairman of the Board for the Clearity Foundation.  Dr. Nelson previously served as Chief Strategy Officer of Provista Diagnostics, President and CEO of a proprietary mobile health “mHealth” company which he sold, Founder/President/Director and CEO of Epic Sciences, Vice President of Business Development of Amalyte Pharmaceuticals, and President of the Life Science Group.  Before that, Dr. Nelson worked at Anadys Pharmaceuticals, Aurora Biosciences, the National Human Genome Research Institute at the National Institutes of Health, 3M, and the University of Minnesota.  Dr. Nelson has been the Principal Investigator on numerous Phase I and II SBIR grants, has a number of peer-reviewed publications, book chapters and patent applications and has been an invited speaker at national meetings in business development, investor relations, and science.

    Mike Norman, Director, San Diego Supercomputer Center
    Dr. Michael L. Norman, named SDSC interim director in June 2009 and appointed to the position of director in September 2010, is a distinguished professor of physics at UC San Diego and a globally recognized astrophysicist. Dr. Norman is a pioneer in using advanced computational methods to explore the universe and its beginnings. In this capacity, he has directed the Laboratory for Computational Astrophysics -- a collaborative effort between UC San Diego and SDSC resulting in the Enzo community code for astrophysics and cosmology in use worldwide. Dr. Norman is the author of over 300 research articles in diverse areas of astrophysics, including star and galaxy formation, the evolution of intergalactic medium, as well as numerical methods. Dr. Norman's work has earned him numerous honors, including Germany's prestigious Alexander von Humboldt Research Prize, the IEEE Sidney Fernbach Award, and several HPCC Challenge Awards. He also is a Fellow of the American Academy of Arts and Sciences, and the American Physical Society. He holds an M.S. and Ph.D. in engineering and applied sciences from UC Davis, and in 1984 completed his post-doctoral work at the Max Planck Institute for Astrophysics in Garching, Germany.

    Chris Orlando, Co-Founder, ScaleMatrix
    Chris is the Co-Founder of ScaleMatrix and leads the company's commercial and strategic efforts.   Prior to ScaleMatrix, Chris served as president of the Complex Drive Data Center Group for four years, in addition to developing a number of hosting and colocation brands in the early 2000’s.  Today, Chris is involved in expanding the reach and breadth of the ScaleMatrix brand, which offers clients some of the highest density, and most energy efficient hosting platforms in the world.
     
    Jeremy Pine, Information Technology Section Chief, California Cancer Registry
    Jeremy Pine re-joined the California Cancer Registry in 2014 after having been with the Cancer Registry previously from 2007-2011. He is an experienced leader with business operations roots that has spent the last several years in technology business development and project management, leading teams in defining, designing, and delivering dozens of high impact web product and enterprise web solutions. His goal is to energize teams by establishing a common vision and deliver valuable software. Jeremy currently serves as the Information Technology Section Chief for the California Cancer Registry managing the organizations electronic reporting initiatives.

    Stephane Richard, President & COO, CureMatch
    With over fifteen years of international business development experience, Stephane brings to CureMatch his experience of the biotech industry, strategy, management and an exceptional network of collaborators. Since 2006, Stephane has been the Founder & President of French BioBeach, an organization promoting business between Southern California and European Life science groups. As an author of 17 scientific papers and 6 patents, Stephane received a Ph.D. in biophysics from the University Joseph Fourier in Grenoble, France. He has served as a scientist at Sapphire Energy, the Salk Institute for Biological Studies, and visiting scientist at the Sanford-Burnham Prebys Medical Discovery Institute, before holding managerial positions in biotech. Stephane acted as CEO of CureMatch since its incorporation in October 2015 until November 2016 and is now acting as President & COO.

    Julie Rodgers, Senior Solution Architect, 3M Information Systems
    Julie Rodgers is a senior strategic operations, program manager, and solution architect with over 20 years of experience in complex and large-scale project management and multi-project program leadership roles. Julie has been with 3M HIS for four years, architecting data solutions to drive population health management and payment reform.  Julie has worked in the healthcare industry for over a decade, managing large projects from payment systems to electronic health records. Prior to 3M, Julie worked as a management consultant, utilizing her technical expertise and operational management skills to simplify complex organizational transitions. Julie has extensive consulting experience in Strategic Planning, Change Management, IT solution design, development, implementation, and production support.
     
    Corina Shtir, Head of Precision Medicine, Thermo Fisher Scientific 
    Dr. Corina Shtir is Head of Precision Medicine at Thermo Fisher Scientific. She joined the company in 2013, from the Wellcome Trust Diabetes and Inflammatory Lab in Cambridge, UK. Her expertise spans many areas, including population genetics, biostatistics, statistical genetics, mathematics, epidemiology, all of which enable her to take an integrative approach to driving population-scale programs for both rare and complex disorders.
    In order to bring Precision Medicine initiatives to scale in a cost-efficient and timely manner, we need to understand the full molecular profile of an individual, including genomics, proteomics, metabolomics, immunology, microenvironment, and microbiome, while managing vast amounts of patient data in a secure and collaborative environment. Thermo Fisher Scientific collaborates and enables some of the most ambitious programs worldwide by providing thought leadership and by creating applications that are implemented at large scale within both the research and clinical environments, driving the entire eco-system of health care through groundbreaking and sustainable solutions. We joined the Cancer Moonshot effort for the Blood Profiling Atlas to develop a public database that will make it easier for oncologists to access liquid biopsy information when diagnosing patients, and work to expand into the new proteogenomic era.
     
    David Wellis, CEO, San Diego Blood Bank
    David is a cell biologist with over 25 years’ experience in the life science industry and currently serves as the CEO of the San Diego Blood Bank (SDBB).  SDBB is dedicated to community health by providing a reliable supply of blood to patients in need throughout Southern California. Our vision is to further ensure the health of our community by simultaneously delivering related health and wellness education and services and extending into research.  SDBB is fortunate to be enrolling All of Us Research Program participants through partnerships with the Scripps Translational Science Institute and the California Precision Medicine Consortium. David joined SDBB following his tenure at a variety of companies that develop biologics, and tools for biomedical research, diagnostic and applied markets, including BioAtla, Illumina, GenVault and Axon Instruments.  David received his B.S. from UC Irvine, an M.S. and Ph.D. from Emory University, postdoctoral training at Tufts University and UC Berkeley, and business training at Leavey Business School of Santa Clara University and Haas Business School at UC Berkeley.

    David Wetherelt, Business Development, 3M Health Information Systems
    David Wetherelt, Director, Business Development for 3M Health Information Systems, has been a leader for organizations that were in the forefront of major technology shifts throughout his career. He has worked to create strategic partnerships with technology and service providers worldwide to enable the deployment of new technologies and business strategies. His focus has been on next generation high-speed mobile networks and innovative voice, video and healthcare technologies. Prior to 3M, he co-founded digifitlife, a next generation healthcare applications and services company. Previously, he was also a Senior Manager with Cisco Systems and held strategic roles at Hearme, Stellent, MapInfo and Interleaf. Follow David on Twitter at @davidwetherelt.
     
    Benjamin Yu, M.D., Ph.D., Vice President, Medical Informatics and Genomics, Interpreta
    Dr. Benjamin Yu is the VP of Medical Informatics and Genomics at Interpreta, a San Diego startup recently named 2017 Cool Vendor in Healthcare by Gartner. Prior to Interpreta, Dr. Yu was on faculty at University of California San Diego and Institute for Genomic Medicine. He brings his experience as a scientific leader in human variation and genomics with more than 10 years of research funded by the NIH, California Institute for Regenerative Medicine, and the Bill and Melinda Gates Foundation. Dr. Yu received his M.D., Ph.D. and residency training at Washington University. Dr. Yu is board-certified in dermatology and has been licensed to practice medicine in California since 2002. He continues to participate in training students and residents in dermatology and pharmacogenomics and serves on Biocom's Big Data Committee.
     
     
     

    a0d2A00000EZ8u4QAD
    Go

Register